Skip Nav Destination
1-6 of 6
Gianluca Cristiano, Jacopo Nanni, Chiara Sartor, Sarah Parisi, Giovanni Marconi, Francesco Barbato, Mario Arpinati, Francesca Bonifazi, Antonio Curti, Michele Cavo, Stefania Paolini, Cristina Papayannidis
Acta Haematol (2021) 144 (6): 688–692.
Published Online: 15 June 2021
... inhibitor ponatinib in obtaining hematological and metabolic remission, in a patient with Philadelphia chromosome-positive de novo T-ALL and outcomes of a therapeutic strategy containing chemotherapy intensification, nelarabine, and allogeneic hematopoietic stem cell transplantation...
Abhishek Maiti, Miguel J. Franquiz, Farhad Ravandi, Jorge E. Cortes, Elias J. Jabbour, Koji Sasaki, Kayleigh Marx, Naval G. Daver, Tapan M. Kadia, Marina Y. Konopleva, Lucia Masarova, Gautam Borthakur, Courtney D. DiNardo, Kiran Naqvi, Sherry Pierce, Hagop M. Kantarjian, Nicholas J. Short
Acta Haematol (2020) 143 (6): 567–573.
Published Online: 09 February 2021
... of prior therapy cycles was 5 (range 2–8). Nine patients received decitabine-based, and 7 received intensive chemotherapy-based regimens. Ten patients (63%) received ponatinib. The overall response rate (ORR) in 15 evaluable patients was 60% (1 complete remission [CR], 6 CR with incomplete hematologic...
Susanne Saussele, Wilhelm Haverkamp, Fabian Lang, Steffen Koschmieder, Alexander Kiani, Kathleen Jentsch-Ullrich, Frank Stegelmann, Heike Pfeifer, Paul La Rosée, Nicola Goekbuget, Christina Rieger, Cornelius F. Waller, Georg-Nikolaus Franke, Philipp le Coutre, Rudolf Kirchmair, Christian Junghanss
Acta Haematol (2020) 143 (3): 217–231.
Published Online: 07 October 2019
... in frontline but also in further lines of therapy. The third-generation TKI ponatinib has demonstrated efficacy in patients with refractory CML and Ph+ ALL. Ponatinib is currently the most potent TKI in this setting demonstrating activity against T315I mutant clones. However, ponatinib’s safety data revealed...
Timothy Devos, Gregor Verhoef, Eva Steel, Dominiek Mazure, Philippe Lewalle, Dominique Bron, Zwi Berneman, Fleur Samantha Benghiat, Philippe Mineur, Koen Theunissen, Pierre Zachée, Chantal Doyen, Natalie Put, Marie Lejeune, Koen Van Eygen, Violaine Havelange, Michael Reusens, Wim Pluymers, Karen Peeters
Acta Haematol (2019) 142 (4): 197–207.
Published Online: 04 June 2019
... to side effects occurred later for imatinib- or dasatinib-treated patients than for those on nilotinib or ponatinib. Treatment was re-initiated in 62% (43/69) of cases. Most interruptions caused by side effects/intolerance were followed by treatment changes. All 4 patients with ≥MR 4.5 at interruption...
Firas El Chaer, Noa G. Holtzman, Edward A. Sausville, Jennie Y. Law, Seung Tae Lee, Vu H. Duong, Maria R. Baer, Rima Koka, Zeba N. Singh, Nancy M. Hardy, Ashkan Emadi
Acta Haematol (2019) 141 (2): 107–110.
Published Online: 29 January 2019
... inhibitor ponatinib, with the achievement of a complete remission lasting 12 months. firstname.lastname@example.org 18 06 2018 24 10 2018 29 1 2019 © 2018 S. Karger AG, Basel 2019 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may...
Acta Haematol (2018) 140 (2): 67–70.
Published Online: 05 September 2018
... revealed hypercellular marrow with eosinophilia and fluorescence in situ hybridization identified the FIP1L1-PDGFRα rearrangement. The patient was successfully treated with imatinib. Within months he relapsed and converted into acute myeloid leukemia. The patient was then treated with ponatinib which...